Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Queensland Health
Daiichi Sankyo

Generated: October 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,529,766

« Back to Dashboard

Summary for Patent: 5,529,766

Title: Contrast agents
Abstract:The invention relates to ultrasound contrast agents comprising vesicles comprising a protein capable of formation of gas-containing vesicles, wherein the vesicles contain gas which comprises sulphur hexafluoride or a low molecular weight fluorinated hydrocarbon. These contrast agents exhibit stability in vivo upon administration so as to permit ultrasound visualization while allowing rapid subsequent elimination from the system.
Inventor(s): Klaveness; Jo (Oslo, NO), Rongved; Pal (Nesoddtaugen, NO), Strande; Per (Oslo, NO)
Assignee: Nycomed Imaging AS (Oslo, NO)
Application Number:08/119,218
Patent Claim Types:
see list of patent claims
Compound; Composition; Process; Use;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,529,766

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9106686Mar 28, 1991
PCT Information
PCT FiledMarch 28, 1992PCT Application Number:PCT/EP92/00716
PCT Publication Date:October 15, 1992PCT Publication Number: WO92/17213

International Patent Family for Patent: 5,529,766

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Spain2082459► Subscribe
Spain2084180► Subscribe
European Patent Office0577659► Subscribe
European Patent Office0807441► Subscribe
Finland934227► Subscribe
Spain2106857► Subscribe
Finland930991► Subscribe
Finland118887► Subscribe
European Patent Office0576521► Subscribe
European Patent Office0547126► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus